Pulmatrix, Inc. (NASDAQ:PULM) Sees Large Decline in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 9,959 shares, a decrease of 59.9% from the May 31st total of 24,832 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 31,504 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned 0.30% of Pulmatrix at the end of the most recent quarter. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Stock Performance

Shares of PULM traded up $0.07 during mid-day trading on Tuesday, reaching $1.70. 15,248 shares of the company’s stock traded hands, compared to its average volume of 49,317. The business’s 50-day moving average price is $1.37 and its 200-day moving average price is $2.01. The stock has a market capitalization of $6.21 million, a P/E ratio of -1.38 and a beta of 1.95. Pulmatrix has a 12 month low of $1.16 and a 12 month high of $7.00.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).